

PROVIDER Update



CONTRACTUAL | APRIL 23, 2025 | UPDATE 25-383m | 4 PAGES

Medication Trend Updates and Formulary Changes – 2nd Quarter 2025

Review drug list, formulary and drug benefit changes and medication safety issues

Stay up to date with information about:

- The Food and Drug Administration (FDA) approves first generic referencing Victoza® (liraglutide injection).
- Changes to drug benefits for Health Net* Medi-Cal members, the Commercial drug lists and the Medicare Part D Formulary for the second quarter of 2025.

FDA approves first generic referencing Victoza (liraglutide injection)

On December 23, 2024, the Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. Liraglutide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes (T2D).

There has been a shortage of GLP-1 medications since 2023 due to high demand driven by the popularity of drugs like Ozempic®, which is approved to treat type 2 diabetes but is used off-label as a weight loss medication. The FDA prioritizes assessment of generic drug applications for drugs in shortage to help improve patient access to these medications.

According to the Office of Generic Drugs in the FDA's Center for Drug Evaluation and Research, generic drugs provide additional treatment options which are generally more affordable for patients. This approval for liraglutide injection emphasizes the FDA's continued commitment to advancing patient access to safe, effective and high-quality generic drug products.

Liraglutide mimics GLP-1, a naturally occurring hormone in the pancreas that regulates blood sugar levels by releasing insulin. The most common side effects of liraglutide injection include nausea, diarrhea, vomiting and decreased appetite. Prescribing information also includes a warning for the potential formation of thyroid C-cell tumors including medullary thyroid carcinoma (MTC). For this reason, patients with a personal or family history of MTC and patients with an endocrine system condition called multiple endocrine neoplasia syndrome type 2 should not use liraglutide.

THIS UPDATE APPLIES TO CALIFORNIA PROVIDERS:

- Physicians
- Participating Physician Groups

LINES OF BUSINESS:

- IFP
 - Ambetter HMO
 - Ambetter PPO
- Employer Group
 - HMO/POS
 - PPO
- Medicare Advantage (HMO) (Wellcare By Health Net)
- Medi-Cal
 - Amador
 - Calaveras
 - Inyo
 - Los Angeles
 - Molina
 - Mono
 - Sacramento
 - San Joaquin
 - Stanislaus
 - Tulare
 - Tuolumne

PROVIDER SERVICES

provider_services@healthnet.com

Ambetter from Health Net IFP

Ambetter PPO – 844-463-8188

Ambetter HMO – 888-926-2164

Health Net Employer Group HMO, POS & PPO – 800-641-7761

Medicare (individual & employer group) (Wellcare By Health Net) – 800-929-9224

Medicare Supplement – 800-641-7761

Medi-Cal (including CS and ECM providers) – 800-675-6110

PROVIDER PORTAL

provider.healthnetcalifornia.com

PROVIDER COMMUNICATIONS

provider.communications@healthnet.com

*Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved. CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at provider.communications@healthnet.com indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

For more information on *FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes*, refer to <https://bit.ly/FDAApprovesFirstGenericGLP>.

Changes to the Commercial Drug Lists, Medi-Cal Drug Benefits and Medicare Part D Formulary

The Health Net Pharmacy Advisory Committee includes practicing physicians, pharmacists and other health care professionals. Each quarter, the Pharmacy Advisory Committee reviews medications on the Drug Lists for Commercial members, Medi-Cal drug benefits, and the Medicare Part D Formulary for Medicare members to determine changes, including which medications remain on the same tier and which are moved. A table listing some recent changes is available on pages 3-4. The list contains brand-name prescription medications, status, other medication choices, and comments for the second quarter of 2025. The complete lists of the Commercial Formularies, Medi-Cal Drug Lists, and Medicare Part D Formularies are available on the Pharmacy Information for Providers page on the provider website at <https://bit.ly/PharmacyInformationforProviders>. For medical drug benefits, refer to the *Outpatient Pharmaceuticals (Submitted Under Medi-Cal Benefit)* section on the Commercial, Health Net Medi-Cal Fee-for Service and Medicare - California Prior Authorization Lists at <https://bit.ly/HealthNetPriorAuthorizations>.

Pharmacy help line

For more information regarding changes to the Health Net Commercial Formulary or Health Net Medi-Cal Drug Lists, or Medicare Part D Formulary, contact the proper pharmacy phone numbers listed below:

Product	Phone number	Fax number
Pharmacy Benefit (Medi-Cal Rx)	800-977-2273	800-869-4325
Medical Benefit Drugs (Medi-Cal)	800-675-6110	833-953-3436
Commercial Pharmacy Services	800-548-5524, option #3	866-399-0929
Medicare Pharmacy Service Center	800-867-6564	800-977-8226

Additional information

If you have questions regarding the information contained in this update, contact the Health Net Provider Services Center by email at provider_services@healthnet.com, by phone or through the Health Net provider portal as listed in the right-hand column on page 1.

Health Net Commercial Drug List, Medi-Cal Drug Benefit and Medicare Part D Formulary Changes

Medication	Status			Health Net Formulary Alternative(s)			Comments
	Commercial Tier 3 plan (Tier 4 plan)	Medicare Part D ¹	Medi-Cal	Commercial (Tier 1 or 2)	Medicare Part D Value ¹	Medi-Cal	

Oral preparation

Aqneursa™ (levacetylleucine) suspension	NF	NF	Carved out to state				Treatment of neurological manifestations of Niemann-Pick (NPC) disease type C in adults and pediatric patients weighing ≥ 15 kg.
Miplyffa™ (arimoclomol) capsule	NF	NF	Carved out to state				Use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients 2 years of age and older.
Revuforj® (revumenib) tablet	NF	NF	Carved out to state				Treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.

Injectable preparation

Liraglutide (by Teva) solution pen injector	NF (Tier 2) ²	NF	Carved out to state				Generic Victoza injection is now available.
Victoza (liraglutide) prefilled, single-patient-use pen	NF	NF	Carved out to state				
Ziihera® (zanidatamab-hrii) single-dose vial	Medical benefit ²	Medical benefit ²	Medical benefit ²	capecitabine (Xeloda®)			Treatment of adults with previously treated, unresectable or metastatic HER2-positive (immunohistochemistry 3+) biliary tract cancer, as detected by an FDA approved test.

Note: The information above is subject to change. Please refer to the Prior Authorization List at <https://bit.ly/HealthNetPriorAuthorizations> for the most up-to-date information.

¹ Medicare Part D: Wellcare CalViva Health Dual Align (HMO D-SNP), Wellcare Dual Align (HMO D-SNP), Wellcare Dual Liberty (HMO D-SNP), Wellcare Low Premium (HMO), Wellcare No Premium (HMO), Wellcare No Premium Focus (HMO), Wellcare No Premium Focus (HMO), Wellcare No Premium Open (PPO), Wellcare No Premium Ruby (HMO), Wellcare Premium Ultra (HMO), Wellcare Specialty No Premium (HMO C-SNP), Wellcare Assist (HMO), Wellcare Patriot Giveback (HMO), Wellcare Dual Liberty Amber (HMO D-SNP), Wellcare Dual Align 001 (HMO D-SNP), Wellcare Dual Liberty (HMO D-SNP), Wellcare Giveback (HMO), Wellcare Giveback Focus (HMO), Wellcare No Premium (HMO), Wellcare No Premium Best (HMO).

² Prior authorization (PA) is required to verify that the member is eligible and satisfies clinical protocols to ensure appropriate use of the medication.

NF indicates nonformulary; NP indicates nonpreferred. These medications require member-specific medical reasons why formulary medications cannot be considered. Requests are reviewed via Health Net's prior authorization process.